参一胶囊联合GP方案治疗晚期非小细胞肺癌临床观察

Clinical Study of GP Regimen Plus Gensing Rg3in Treatment of Advanced Non-small Cell Lung Cancer

目的观察参一胶囊联合GP方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效和患者的耐受性。方法 77例晚期非小细胞肺癌患者随机分组,治疗组39例采用参一胶囊加GP方案;对照组38例,仅采用GP方案。结果治疗组近期有效率48.7%,临床获益率82.1%;对照组有效率36.8%,临床获益率63.2%,有效率两组比较差异无统计学意义(P>0.05),临床获益率两组比较差异有统计学意义(P<0.05)。主要不良反应为骨髓抑制和恶心呕吐,治疗组Ⅲ/Ⅳ度反应明显低于对照组,两组比较差异有统计学意义。结论参一胶囊联合GP方案对晚期非小细胞肺癌具有增加疗效,减轻不良反应,提高患者耐受性的作用,值得临床推广应用。

Objective To study the clinical effect and toleration of Rg3combination with chemotherapy regimen—GP in patients with advanced non-small cell lung cancer（NSCLC）.Methods Seventy-seven patients were divided into two groups randomly.Thirty-nine patients as treatment group,treated by Rg3 plus GP regimen,and thirty-eight patients as the control group,only treated by GP regimen.Results The response rate was 48.7%in treatment group and 36.8%in control,The clinical benefit rate（disease control rate）was 82.1%and 63.2% respectively（P〈0.05）.Conclusion Rg3combined with GP regimen could increase the therapeutic effects and decrease the side effects of chemotherapy in the patients with advanced non-small cell lung cancer.